Inari Medical

Inari Medical, Inc. operates as a medical device company. The firm develops, manufactures, markets and sells devices for the interventional treatment of venous diseases. Its products include FlowTriever system and ClotTriever system. The company was founded by Brian J. Cox, Paul Lubock and Robert F. Rosenbluth in July 2011 and is headquartered in Irvine, CA.

Earnings data Q1 2020

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Inari Medical reports robust Q4 earnings and eyes international expansion

Inari Medical's Q4 2022 earnings call highlighted strong revenue growth, operational challenges, and strategic opportunities for market expansion and product innovation.
The company's focus on patient outcomes, superior product performance, and international growth positions it for continued success in 2023 and beyond.
Efforts to optimize gross margins, manage operating expenses, and drive market adoption present key areas for Inari's future financial performance and profitability.
With a clear revenue guidance for 2023 and a commitment to sustained operating profitability, Inari Medical demonstrates a strategic roadmap for sustainable growth.

Inari Medical reports robust Q1 earnings, eyes sustained profitability

Inari Medical's Q1 earnings call highlighted strong financial performance, growth strategies, and product innovations. Challenges include competitive dynamics and assessing seasonality trends. The company is well-positioned for sustained growth and market expansion.

Inari Medical reports record revenue and eyes Asian market expansion

Inari Medical's Q2 2023 performance reflects robust financial growth, international expansion, and a strategic focus on addressing unmet needs in the CVD market.
With a strong product portfolio, sustained profitability, and market development initiatives, Inari Medical is well-equipped to capitalize on growth opportunities and drive innovation.
Challenges in market entry, product redesign timelines, and regulatory approvals are being navigated as the company aims for sustained growth and market leadership in the medical device sector.

Inari Medical reports robust Q3 earnings, acquires LimFlow for growth

Inari Medical's Q3 performance reflects strong financial growth, operational improvements, and strategic acquisitions driving future prospects.
While challenges like declining margins and delayed profit targets exist, opportunities in new markets, product pricing, and synergies offer avenues for sustained growth.
The LimFlow acquisition positions Inari well in the CLTI market, with a focus on revenue growth, operational efficiency, and market expansion.
Overall, Inari's confidence in its core business and strategic moves like the LimFlow acquisition signal a positive trajectory and growth outlook.

Inari Medical reports record revenue, eyes sustained profitability amid challenges

Inari Medical's Q4 2023 performance showcased strong revenue growth, operational progress, and a strategic focus on market leadership and patient care.
While facing challenges such as regulatory scrutiny and increased operating expenses, the company remains optimistic about revenue growth and sustained profitability.
Opportunities lie in diversified revenue streams, international expansion, and product portfolio enhancements, positioning Inari for continued growth and market leadership.
Overall, Inari Medical's strategic initiatives and financial performance indicate a resilient and growth-oriented trajectory in the medical device industry.

Inari Medical reports record Q1 revenue, raises full-year guidance

Inari Medical's Q1 performance reflects robust revenue growth, strategic investments, and international expansion, positioning the company for sustained profitability and market leadership.
While facing challenges in competition and market dynamics, Inari's strengths in innovation, global performance, and product development offer avenues for growth and differentiation.
The company's focus on operational efficiency, strategic investments, and product enhancements align with opportunities in expanding toolkits, new therapies, and market presence.

Inari Medical reports record revenue, eyes sustained profitability and global expansion

Inari Medical's Q2 2024 performance reflects strong revenue growth but with operating losses, signaling a need for cost management strategies.
The company's strategic strengths lie in sustained profitability projections, successful business integrations, and expansion into key international markets.
Challenges include leadership transition risks, operational hurdles in new markets, and the need to meet high market expectations with upcoming data releases.
Opportunities for Inari include optimizing costs, leveraging growth in China and Japan, capitalizing on new product adoption, and driving further market expansion.

Inari Medical reports record revenue and eyes global expansion

Inari Medical's Q3 performance reflects robust revenue growth and strategic focus on expanding therapies globally.
The company's strengths lie in revised revenue guidance, upcoming profitability, and promising study outcomes.
Challenges include managing expenses, reducing losses, and sustaining high margins amidst market competition.
Opportunities abound in driving growth, capitalizing on new therapies, and expanding market presence internationally.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Inari Medical, Inc. operates as a medical device company. The firm develops, manufactures, markets and sells devices for the interventional treatment of venous diseases. Its products include FlowTriever system and ClotTriever system. The company was founded by Brian J. Cox, Paul Lubock and Robert F. Rosenbluth in June 2011 and is headquartered in Irvine, CA.

Start Time: 16:30 January 1, 0000 2:24 PM ET Inari Medical, Inc. (NASDAQ:NARI ) Q2 2024 Earnings Conference Call July 30, 2024, 16:30 PM ET Company Participants Drew Hykes - President and CEO Mitch Hill - CFO Tom Tu - Chief Medical Officer Kevin Strange - SVP of Finance, Accounting, Strategy and Business Development Marissa Bych - Gilmartin Group LLC Conference Call Participants Kallum Titchmarsh - Morgan Stanley Stephanie Pezzi - Bank of America Marie Thibault - BTIG Bill Plovanic - Canaccord Chris Pasquale - Nephron Research Adam Maeder - Piper Sandler Richard Newitter - Truist Margaret Kaczor - William Blair Operator Good afternoon, everyone, and welcome to the Inari Medical, Inc. Second Quarter 2024 Earnings Conference Call. All participants are in a listen-only mode.

Inari Medical, Inc. (NARI) Q2 2024 Earnings Call Transcript

Revenue increased by 22.5% year over year to $145.8 million. The healthcare company reported a significant net loss of $31.3 million, in contrast to its net profit of $2.1 million in the prior-year period.

Inari Medical's Renenue Rises, but Bottom Line Remains in the Red

Inari Medical, Inc. (NARI) came out with a quarterly loss of $0.41 per share versus the Zacks Consensus Estimate of a loss of $0.16. This compares to earnings of $0.04 per share a year ago.

Inari Medical, Inc. (NARI) Reports Q2 Loss, Tops Revenue Estimates

Mitch Hill to retire as Chief Financial Officer, to be succeeded by Kevin Strange in October 2024 Mitch Hill to retire as Chief Financial Officer, to be succeeded by Kevin Strange in October 2024

Inari Medical Announces Chief Financial Officer Retirement and Succession Plan

Inari Medical (NARI) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Inari Medical, Inc. (NARI) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release

IRVINE, Calif., July 16, 2024 (GLOBE NEWSWIRE) -- Inari Medical, Inc. (NASDAQ: NARI) (“Inari”), a medical device company with a mission to treat and transform the lives of patients suffering from venous and other diseases, today announced that it will release its second quarter 2024 financial results on Tuesday, July 30, 2024. In conjunction with the release, Inari will host a conference call and webcast at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time to discuss its financial results and recent highlights.

Inari Medical to Announce Second Quarter 2024 Financial Results

NEW YORK, NY / ACCESSWIRE / July 12, 2024 / If you suffered a loss on your Inari Medical, Inc. (NASDAQ:NARI) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/inari-medical-inc-lawsuit-submission-form?prid=90574&wire=1 or contact Joseph E. Levi, Esq.

Inari Medical, Inc. Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before July 12, 2024 to Discuss Your Rights - NARI

NEW YORK, July 12, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Inari Medical, Inc. (“Inari” or the “Company”) (NASDAQ: NARI).   Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.

SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against Inari Medical, Inc. – NARI

NEW YORK, NY / ACCESSWIRE / July 12, 2024 / If you suffered a loss on your Inari Medical, Inc. (NASDAQ:NARI) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/inari-medical-inc-lawsuit-submission-form?prid=90550&wire=1 or contact Joseph E. Levi, Esq.

Investors in Inari Medical, Inc. Should Contact Levi & Korsinsky Before July 12, 2024 to Discuss Your Rights - NARI

NEW YORK, NY / ACCESSWIRE / July 12, 2024 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Inari Medical, Inc. ("Inari" or "the Company") (NASDAQ:NARI) and certain of its officers. Class Definition: This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Inari securities between March 10, 2021 and February 28, 2024, inclusive (the "Class Period").

FINAL NARI DEADLINE: Bronstein, Gewirtz & Grossman LLC Reminds Inari Medical, Inc. Investors to Join the Class Action Lawsuit!

NEW YORK, NY / ACCESSWIRE / July 12, 2024 / If you suffered a loss on your Inari Medical, Inc. (NASDAQ:NARI) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/inari-medical-inc-lawsuit-submission-form?prid=90545&wire=1 or contact Joseph E. Levi, Esq.

Shareholders that lost money on Inari Medical, Inc. (NARI) should contact Levi & Korsinsky about pending Class Action - NARI

NEW YORK, NY / ACCESSWIRE / July 12, 2024 / If you suffered a loss on your Inari Medical, Inc. (NASDAQ:NARI) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/inari-medical-inc-lawsuit-submission-form?prid=90529&wire=1 or contact Joseph E. Levi, Esq.

Shareholders that Lost Money on Inari Medical, Inc.(NARI) Should Contact Levi & Korsinsky About Pending Class Action - NARI

LOS ANGELES, CA / ACCESSWIRE / July 12, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Inari Medical, Inc. ("Inari" or "the Company") (NASDAQ:NARI) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between February 24, 2022 and February 28, 2024, inclusive (the "Class Period"), are encouraged to contact the firm before July 12, 2024.

The Schall Law Firm Calls On Shareholders Who Suffered Losses In Inari Medical Inc To Start Conversation As It Begins A Probe

NEW YORK, NY / ACCESSWIRE / July 12, 2024 / If you suffered a loss on your Inari Medical, Inc. (NASDAQ:NARI) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/inari-medical-inc-lawsuit-submission-form?prid=90523&wire=1 or contact Joseph E. Levi, Esq.

Levi & Korsinsky Reminds Inari Medical, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of July 12, 2024 - NARI

LOS ANGELES, July 12, 2024 (GLOBE NEWSWIRE) -- The Schall Law Firm , a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Inari Medical, Inc. (“Inari” or “the Company”) (NASDAQ: NARI ) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between February 24, 2022 and February 28, 2024, inclusive (the “Class Period”), are encouraged to contact the firm before July 12, 2024.

NARI Investors Have Opportunity to Lead Inari Medical, Inc. Securities Fraud Lawsuit with the Schall Law Firm

NEW YORK , July 12, 2024 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Inari Medical, Inc. (NASDAQ: NARI). Shareholders who purchased shares of NARI during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment.

Investors who lost money on Inari Medical, Inc.(NARI) should contact The Gross Law Firm about pending Class Action - NARI

NEW YORK, NY / ACCESSWIRE / July 11, 2024 / If you suffered a loss on your Inari Medical, Inc. (NASDAQ:NARI) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/inari-medical-inc-lawsuit-submission-form?prid=90439&wire=1 or contact Joseph E. Levi, Esq.

Shareholders that lost money on Inari Medical, Inc.(NARI) Urged to Join Class Action – Contact Levi & Korsinsky to Learn More

SAN FRANCISCO, CA / ACCESSWIRE / July 11, 2024 / Hagens Berman urges Inari Medical, Inc. (NASDAQ:NARI) investors who suffered substantial losses to submit your losses now. Class Period: Feb. 24, 2022 - Feb. 28, 2024 Lead Plaintiff Deadline: July 12, 2024 Visit: www.hbsslaw.com/investor-fraud/nari Contact the Firm Now: NARI@hbsslaw.com 844-916-0895 Inari Medical Class Action: Inari Medical, Inc. (NASDAQ: NARI), a leading medical device manufacturer, finds itself embroiled in a complex legal battle as the U.S. Department of Justice (DOJ) intensifies its scrutiny.

Contact Hagens Berman by July 12, 2024 Deadline to Join Class Action Against Inari Medical (NARI)

NEW YORK, NY / ACCESSWIRE / July 11, 2024 / If you suffered a loss on your Inari Medical, Inc. (NASDAQ:NARI) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/inari-medical-inc-lawsuit-submission-form?prid=90432&wire=1 or contact Joseph E. Levi, Esq.

Inari Medical, Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky for More Information - NARI

NEW YORK, NY / ACCESSWIRE / July 11, 2024 / If you suffered a loss on your Inari Medical, Inc. (NASDAQ:NARI) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/inari-medical-inc-lawsuit-submission-form?prid=90409&wire=1 or contact Joseph E. Levi, Esq.

Inari Medical, Inc. Sued for Securities Law Violations - Contact Levi & Korsinsky Before July 12, 2024 to Discuss Your Rights - NARI

Contact Hagens Berman by July 12, 2024 Deadline to Join Class Action Against Inari Medical (NARI) Contact Hagens Berman by July 12, 2024 Deadline to Join Class Action Against Inari Medical (NARI)

Did Inari Medical (NARI) Buy Sales? Investor Lawsuit Claims Kickbacks Fueled Revenue – Hagens Berman

LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz reminds investors of the upcoming July 12, 2024 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who acquired Inari Medical, Inc. (“Inari” or the “Company”) (NASDAQ: NARI) common stock between March 10, 2021 through February 28, 2024, inclusive (the “Class Period”). If you are a shareholder who suffered a loss, click here to participate. On February 29, 2024, Inari announced that it had recei.

The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Inari Medical, Inc. (NARI)

NEW YORK, NY / ACCESSWIRE / July 11, 2024 / If you suffered a loss on your Inari Medical, Inc. (NASDAQ:NARI) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/inari-medical-inc-lawsuit-submission-form?prid=90395&wire=1 or contact Joseph E. Levi, Esq.

Lost Money on Inari Medical, Inc. (NARI)? Join Class Action Suit Seeking Recovery - Contact Levi & Korsinsky

NEW YORK, NY / ACCESSWIRE / July 11, 2024 / If you suffered a loss on your Inari Medical, Inc. (NASDAQ:NARI) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/inari-medical-inc-lawsuit-submission-form?prid=90383&wire=1 or contact Joseph E. Levi, Esq.

Inari Medical, Inc. Class Action: Levi & Korsinsky Reminds Inari Medical Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of July 12, 2024 - NARI

LOS ANGELES, CA / ACCESSWIRE / July 11, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Inari Medical, Inc. ("Inari" or "the Company") (NASDAQ:NARI) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between February 24, 2022 and February 28, 2024, inclusive (the "Class Period"), are encouraged to contact the firm before July 12, 2024.

News for Inari Medical Stock (NARI)